LIVIVO - Search results -

Search results

Result 1 - 10 of total 32

Search options

Article: Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study.

Bilgic, Alper / Kodjikian, Laurent / Srivastava, Samaresh / Dwivedi, Shyamal / Banker, Alay S / Abukashabah, Amro / Sudhalkar, Aditya / Mathis, Thibaud

Journal of clinical medicine

2021 Volume 10, Issue 18

Abstract: The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata ... ...

Abstract	The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata Brolucizumab for Exudative AMD) is a retrospective, observational, multicentric study that included 27 treatment-naïve patients (27 eyes) with neovascular AMD who received PRN brolucizumab therapy with the treatment interval being at least 8 weeks, should the need for a second consecutive injection arise. The primary outcome measure was changed to best-corrected visual acuity (BCVA) over time. Secondary outcome measures included the determination of change in central subfield thickness (CST) and complications. The mean follow-up was 11.2 ± 1.2 months. The mean baseline and final BCVA were 57.4 ± 4.5 letters and 65.3 ± 3.12 letters, respectively (
Language	English
Publishing date	2021-09-15
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm10184153
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Posterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome.

Banker, Alay S

Indian journal of ophthalmology

2008 Volume 56, Issue 5, Page(s) 377–383

Abstract: Ocular manifestations can occur in up to 50% of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) patients and posterior segment involvement is the most common presentation. The posterior segment manifestations of AIDS can be ... ...

Abstract	Ocular manifestations can occur in up to 50% of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) patients and posterior segment involvement is the most common presentation. The posterior segment manifestations of AIDS can be divided into four categories: retinal vasculopathy, opportunistic infections, unusual malignancies and neuro-ophthalmologic abnormalities. Retinal microvasculopathy and cytomegalovirus (CMV) retinitis are the most common manifestations, even in the era of highly active anti-retroviral therapy (HAART). Highly active anti-retroviral therapy has been shown to cause regression of CMV retinitis, reduce the incidence of CMV-related retinal detachments, and prolong patient survival. Immune recovery uveitis is a new cause of vision loss in patients on HAART. Diagnosis and treatment are guided by the particular conditions and immune status of the patient.
MeSH term(s)	AIDS-Related Opportunistic Infections/drug therapy ; AIDS-Related Opportunistic Infections/epidemiology ; AIDS-Related Opportunistic Infections/virology ; Anti-Retroviral Agents/therapeutic use ; HIV ; Humans ; India/epidemiology ; Morbidity/trends ; Prognosis ; Uveitis, Posterior/drug therapy ; Uveitis, Posterior/epidemiology ; Uveitis, Posterior/virology
Chemical Substances	Anti-Retroviral Agents
Language	English
Publishing date	2008-08-18
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	187392-1
ISSN	0301-4738
ISSN	0301-4738
DOI	10.4103/0301-4738.42413
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 329: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 598: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Initial Pro Re Nata Brolucizumab for Exudative AMD

Alper Bilgic / Laurent Kodjikian / Samaresh Srivastava / Shyamal Dwivedi / Alay S Banker / Amro Abukashabah / Aditya Sudhalkar / Thibaud Mathis

Journal of Clinical Medicine, Vol 10, Iss 4153, p

The PROBE Study

2021 Volume 4153

Abstract	The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata Brolucizumab for Exudative AMD) is a retrospective, observational, multicentric study that included 27 treatment-naïve patients (27 eyes) with neovascular AMD who received PRN brolucizumab therapy with the treatment interval being at least 8 weeks, should the need for a second consecutive injection arise. The primary outcome measure was changed to best-corrected visual acuity (BCVA) over time. Secondary outcome measures included the determination of change in central subfield thickness (CST) and complications. The mean follow-up was 11.2 ± 1.2 months. The mean baseline and final BCVA were 57.4 ± 4.5 letters and 65.3 ± 3.12 letters, respectively ( p = 0.014). The mean gain in letters at the end of follow-up was 7.8 ± 3.5 letters. There was a significant decrease in CST at the end of the follow-up period ( p = 0.013). Patients received a mean of 2.2 ± 0.9 injections (in addition to the first mandatory injection) during the follow-up period. There were no adverse events noted. In conclusion, initial PRN brolucizumab for exudative AMD without a loading dose demonstrated significant visual improvement and no adverse events.
Keywords	age-related macular degeneration ; anti-vascular endothelial growth factor ; brolucizumab ; exudation ; treatment-naive ; Medicine ; R
Subject code	616
Language	English
Publishing date	2021-09-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Comparison of RetCam and Smartphone-Based Photography for Retinopathy of Prematurity Screening.

Lin, Jui-Yen / Kang, Eugene Yu-Chuan / Banker, Alay S / Chen, Kuan-Jen / Hwang, Yih-Shiou / Lai, Chi-Chun / Huang, Jhen-Ling / Wu, Wei-Chi

Diagnostics (Basel, Switzerland)

2022 Volume 12, Issue 4

Abstract: ... had moderate agreement with the BIO results regarding the presence or absence of plus disease (Cohen’s ...

Abstract	This study aimed to compare the clinical performance between a smartphone-based fundus photography device and a contact imaging device for retinopathy of prematurity (ROP) screening. All patients were first examined with binocular indirect ophthalmoscopy (BIO), which served as the reference standard. The patients were then assessed by two devices. Imaging quality, ability to judge the zone and stage of ROP, agreement with the BIO results, vital signs, and pain scores were compared between these two devices. In total, 142 eyes of 71 infants were included. For the smartphone-based fundus photography, image quality was graded excellent or acceptable in 91.4% of examinations, although it was still significantly inferior to that of the contact imaging device (p < 0.001). The smartphone-based fundus photography images had moderate agreement with the BIO results regarding the presence or absence of plus disease (Cohen’s κ = 0.619), but evaluating the zone (p < 0.001) and stage (p < 0.001) of ROP was difficult. Systemic parameters, except for heart rate, were similar between the two imaging devices (all p > 0.05). In conclusion, although the smartphone-based fundus photography showed moderate agreement for determining the presence or absence of plus disease, it failed to identify the zone and stage of ROP.
Language	English
Publishing date	2022-04-10
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662336-5
ISSN	2075-4418
ISSN	2075-4418
DOI	10.3390/diagnostics12040945
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Comparison of RetCam and Smartphone-Based Photography for Retinopathy of Prematurity Screening

Jui-Yen Lin / Eugene Yu-Chuan Kang / Alay S. Banker / Kuan-Jen Chen / Yih-Shiou Hwang / Chi-Chun Lai / Jhen-Ling Huang / Wei-Chi Wu

Diagnostics, Vol 12, Iss 945, p

2022 Volume 945

Abstract: ... had moderate agreement with the BIO results regarding the presence or absence of plus disease (Cohen’s ...

Abstract	This study aimed to compare the clinical performance between a smartphone-based fundus photography device and a contact imaging device for retinopathy of prematurity (ROP) screening. All patients were first examined with binocular indirect ophthalmoscopy (BIO), which served as the reference standard. The patients were then assessed by two devices. Imaging quality, ability to judge the zone and stage of ROP, agreement with the BIO results, vital signs, and pain scores were compared between these two devices. In total, 142 eyes of 71 infants were included. For the smartphone-based fundus photography, image quality was graded excellent or acceptable in 91.4% of examinations, although it was still significantly inferior to that of the contact imaging device ( p < 0.001). The smartphone-based fundus photography images had moderate agreement with the BIO results regarding the presence or absence of plus disease (Cohen’s κ = 0.619), but evaluating the zone ( p < 0.001) and stage ( p < 0.001) of ROP was difficult. Systemic parameters, except for heart rate, were similar between the two imaging devices (all p > 0.05). In conclusion, although the smartphone-based fundus photography showed moderate agreement for determining the presence or absence of plus disease, it failed to identify the zone and stage of ROP.
Keywords	imaging systems ; smartphone-based screen ; telescreening ; retinopathy of prematurity ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2022-04-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.

Merrill, Pauline T / Clark, W Lloyd / Banker, Alay S / Fardeau, Christine / Franco, Pablo / LeHoang, Phuc / Ohno, Shigeaki / Rathinam, Sivakumar R / Ali, Yusuf / Mudumba, Sri / Shams, Naveed / Nguyen, Quan Dong

Ophthalmology

2020 Volume 127, Issue 10, Page(s) 1405–1415

Abstract: Purpose: To evaluate the efficacy and safety of intravitreal sirolimus in the management of noninfectious uveitis of the posterior segment (NIU-PS).: Design: Combined analysis of 2 phase 3, randomized, double-masked, multinational, 6-month studies.!## ...

Abstract	Purpose: To evaluate the efficacy and safety of intravitreal sirolimus in the management of noninfectious uveitis of the posterior segment (NIU-PS). Design: Combined analysis of 2 phase 3, randomized, double-masked, multinational, 6-month studies. Participants: Adults with active NIU-PS (intermediate uveitis, posterior uveitis, or panuveitis; defined as vitreous haze [VH] ≥1.5+ on modified Standardization of Uveitis Nomenclature scale). Methods: Patients were randomized 1:1:1 to receive intravitreal sirolimus 44 μg (n = 208), 440 μg (n = 208), or 880 μg (n = 177) on days 1, 60, and 120. Patients discontinued medications for NIU-PS except for systemic corticosteroids, which were tapered according to protocol. Enrollment in the 880-μg group was terminated after interim results found no significant difference in efficacy compared with the 440-μg dose. Main outcome measures: The primary efficacy end point was the percentage of patients with VH of 0 at month 5 in the study eye without the use of rescue therapy. Secondary efficacy end points included VH of 0 or 0.5+, corticosteroid-tapering success, and changes in best-corrected visual acuity (BCVA). Safety measures included ocular and nonocular adverse events. Results: A total of 592 patients were randomized. Significantly higher proportions of patients treated with 440 μg compared with 44 μg intravitreal sirolimus achieved VH of 0 (21.2% vs. 13.5%; P = 0.038) and VH of 0 or 0.5+ (50.0% vs. 40.4%; P = 0.049) at month 5. Best-corrected visual acuity was stable (absolute change <5 ETDRS letters) or improved >5 letters in 80.1% and 80.2% of patients in the 440-μg and 44-μg groups, respectively. At month 5, corticosteroids were tapered successfully in 69.6% and 68.8% of patients in the 440-μg and 44-μg groups, and among these patients, VH of 0 or 0.5+ was achieved by 43.5% and 28.1% in the 440-μg and 44-μg groups. Both doses were generally well tolerated. Mean changes from baseline intraocular pressure (IOP) in the study eye at each analysis visit were minimal in all treatment groups. Conclusions: Intravitreal sirolimus 440 μg improved ocular inflammation, as measured by VH, compared with the 44-μg dose, with minimal impact on IOP, while preserving BCVA.
MeSH term(s)	Aged ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/administration & dosage ; Intraocular Pressure/drug effects ; Intravitreal Injections ; Male ; Posterior Eye Segment/diagnostic imaging ; Sirolimus/administration & dosage ; Tomography, Optical Coherence/methods ; Uveitis, Posterior/diagnosis ; Uveitis, Posterior/drug therapy
Chemical Substances	Immunosuppressive Agents ; Sirolimus (W36ZG6FT64)
Language	English
Publishing date	2020-04-03
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	392083-5
ISSN	1549-4713 ; 0161-6420
ISSN (online)	1549-4713
ISSN	0161-6420
DOI	10.1016/j.ophtha.2020.03.033
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ul II Zs.83: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 533: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Endogenous Endophthalmitis A Complication of COVID-19 Pandemic: A Case Series.

Agarwal, Manisha / Sachdeva, Mani / Pal, Surendra / Shah, Harita / Kumar R, Madhu / Banker, Alay

Ocular immunology and inflammation

2021 Volume 29, Issue 4, Page(s) 726–729

Abstract: Purpose: To report six patients with endogenous endophthalmitis as a complication of COVID-19 infection.: Methods: A multicentric retrospective database review of patients with a diagnosis of endogenous endophthalmitis and a history of COVID-19 ... ...

Abstract	Purpose: To report six patients with endogenous endophthalmitis as a complication of COVID-19 infection. Methods: A multicentric retrospective database review of patients with a diagnosis of endogenous endophthalmitis and a history of COVID-19 infection. Results: Four of six patients were diabetics. All presented after an average duration of 40 days (Range 17-90 days) of COVID-19 infection. Two of six patients had bilateral involvement. Five of six patients had received intravenous corticosteroid for COVID-19. Two of six vitreous samples showed fungi ( Conclusions: COVID-19 patients with a history of hospitalization and prolonged use of systemic corticosteroids and comorbidities, for example, diabetes mellitus have a high risk of endogenous endophthalmitis. A high index of clinical suspicion with timely intervention can salvage many eyes.
MeSH term(s)	Adult ; Bacteria/isolation & purification ; COVID-19/complications ; COVID-19/epidemiology ; Endophthalmitis/diagnosis ; Endophthalmitis/etiology ; Endophthalmitis/microbiology ; Eye Infections, Bacterial/diagnosis ; Eye Infections, Bacterial/etiology ; Eye Infections, Bacterial/microbiology ; Eye Infections, Fungal/diagnosis ; Eye Infections, Fungal/etiology ; Eye Infections, Fungal/microbiology ; Follow-Up Studies ; Fungi/isolation & purification ; Humans ; India/epidemiology ; Male ; Middle Aged ; Pandemics ; Retrospective Studies ; Visual Acuity ; Vitreous Body/microbiology
Language	English
Publishing date	2021-07-13
Publishing country	England
Document type	Case Reports ; Journal Article ; Multicenter Study
ZDB-ID	1193873-0
ISSN	1744-5078 ; 0927-3948
ISSN (online)	1744-5078
ISSN	0927-3948
DOI	10.1080/09273948.2021.1945111
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4004: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Degenerated intravitreal cysticercus cyst masquerading as endogenous endophthalmitis.

Mulla, Mohammad Arif / Banker, Alay S / Rishi, Ekta / Biswas, Jyotirmay

Ocular immunology and inflammation

2012 Volume 20, Issue 5, Page(s) 378–380

Abstract: The authors report a case of degenerated intravitreal cysticercus cyst presenting as endogenous endophthalmitis, which has hitherto been unreported. A young adult presented with symptoms of chronic bilateral ocular inflammation, and was treated topically ...

Abstract	The authors report a case of degenerated intravitreal cysticercus cyst presenting as endogenous endophthalmitis, which has hitherto been unreported. A young adult presented with symptoms of chronic bilateral ocular inflammation, and was treated topically for endogenous endophthalmitis in the left eye. On dilated fundus examination the right eye was found to have a cystic structure in the inferior vitreous cavity. The cyst was removed by a three-port vitrectomy. On submitting the vitreous sample to histopathology it was confirmed to be degenerated cysticerus cyst with chronic inflammation.
MeSH term(s)	Adolescent ; Animals ; Cysticercosis/drug therapy ; Cysticercosis/pathology ; Cysticercosis/surgery ; Cysticercus/isolation & purification ; Cysts/diagnosis ; Cysts/pathology ; Cysts/surgery ; Diagnostic Errors ; Endophthalmitis/pathology ; Fundus Oculi ; Humans ; Male ; Treatment Outcome ; Uveitis/diagnosis ; Uveitis/pathology ; Uveitis/surgery ; Vitrectomy ; Vitreous Body/pathology ; Vitreous Body/surgery
Language	English
Publishing date	2012-10
Publishing country	England
Document type	Case Reports ; Letter
ZDB-ID	1193873-0
ISSN	1744-5078 ; 0927-3948
ISSN (online)	1744-5078
ISSN	0927-3948
DOI	10.3109/09273948.2012.700991
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4004: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Human immunodeficiency virus and intraocular inflammation in the era of highly active anti retroviral therapy - An update.

Sudharshan, Sridharan / Nair, Nivedita / Curi, Andre / Banker, Alay / Kempen, John H

Indian journal of ophthalmology

2020 Volume 68, Issue 9, Page(s) 1787–1798

Abstract: Intraocular inflammation in patients with human immunodeficiency virus (HIV) infection is commonly due to infectious uveitis. Ocular lesions due to opportunistic infections (OI) are the most common and have been described extensively in the pre highly ... ...

Abstract	Intraocular inflammation in patients with human immunodeficiency virus (HIV) infection is commonly due to infectious uveitis. Ocular lesions due to opportunistic infections (OI) are the most common and have been described extensively in the pre highly active antiretroviral therapy (HAART) era. Many eye lesions were classified as acquired immunodeficiency syndrome (AIDS) defining illnesses. HAART-associated improvement in immunity of the individual has changed the pattern of incidence of these hitherto reported known lesions leading to a marked reduction in the occurrence of ocular OI. Newer ocular lesions and newer ocular manifestations of known agents have been noted. Immune recovery uveitis (IRU), the new menace, which occurs as part of immune recovery inflammatory syndrome (IRIS) in the eye, can present with significant ocular inflammation and can pose a diagnostic and therapeutic challenge. Balancing the treatment of inflammation with the risk of reactivation of OI is a task by itself. Ocular involvement in the HAART era can be due to the adverse effects of some systemic drugs used in the management of HIV/AIDS. Drug-associated retinal toxicity and other ocular side effects are being increasingly reported. In this review, we discuss the ocular manifestations in HIV patients and its varied presentations following the introduction of HAART, drug-associated lesions, and the current treatment guidelines.
MeSH term(s)	AIDS-Related Opportunistic Infections/drug therapy ; Antiretroviral Therapy, Highly Active/adverse effects ; Cytomegalovirus Retinitis ; HIV ; HIV Infections/complications ; HIV Infections/drug therapy ; Humans ; Inflammation/drug therapy ; Uveitis/diagnosis ; Uveitis/drug therapy
Language	English
Publishing date	2020-08-21
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	187392-1
ISSN	1998-3689 ; 0301-4738
ISSN (online)	1998-3689
ISSN	0301-4738
DOI	10.4103/ijo.IJO_1248_20
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 329: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 598: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: SURGICAL OUTCOMES AND COMPLICATIONS OF RHEGMATOGENOUS RETINAL DETACHMENT IN EYES WITH CHORIORETINAL COLOBOMA: The Results of the KKESH International Collaborative Retina Study Group.

Abouammoh, Marwan A / Alsulaiman, Sulaiman M / Gupta, Vishali S / Younis, Afnan / Chhablani, Jay / Hussein, Abdullah / Casella, Antonio M / Banker, Alay S / Arevalo, J Fernando

Retina (Philadelphia, Pa.)

2017 Volume 37, Issue 10, Page(s) 1942–1947

Abstract: Purpose: To study the outcomes of management of rhegmatogenous retinal detachment in eyes with chorioretinal colobomas.: Methods: A retrospective review of 119 patients (119 eyes) with chorioretinal colobomas who underwent surgical repair for ... ...

Abstract	Purpose: To study the outcomes of management of rhegmatogenous retinal detachment in eyes with chorioretinal colobomas. Methods: A retrospective review of 119 patients (119 eyes) with chorioretinal colobomas who underwent surgical repair for rhegmatogenous retinal detachment was performed. Data were collected on the site of the retinal break, type of surgery, anatomical success, and complications. Results: The most common location of the primary retinal break was the intercalary membrane in 58.8% of eyes. The most common surgical intervention was vitrectomy with endolaser and silicone oil tamponade (77.3% of eyes). Final anatomical success was achieved in 87.4% of eyes. Anatomical success was significantly higher in eyes that received long-acting tamponade (P = 0.006). Cryotherapy was significantly associated with failure of primary vitrectomy (P = 0.028). Placement of an encircling band did not affect anatomical outcomes (P = 0.75). Most of the eyes (60%) with recurrent retinal detachment after primary vitrectomy had a primary break within the normal retina. Conclusion: The optimal option for managing retinal detachment in eyes with chorioretinal colobomas is pars plana vitrectomy with long-acting tamponade (silicone oil or octafluoropropane) and retinopexy to the edge of the coloboma and the primary breaks. Cryotherapy is associated with poor anatomical outcomes. An encircling band does not seem to affect the final anatomical outcome.
Language	English
Publishing date	2017-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	603192-4
ISSN	1539-2864 ; 0275-004X
ISSN (online)	1539-2864
ISSN	0275-004X
DOI	10.1097/IAE.0000000000001444
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1724: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito